News

Unusual colon lesions caused by ischemic colitis led to the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) in an 82-year-old woman in Japan, but appropriate treatment eased her symptoms. According to the authors, her case highlights the importance of considering underlying diseases when unusual features are observed in a person…

Treatment with OMS906 is showing an ability to normalize all markers of red blood cell destruction, or hemolysis, in severely anemic people with paroxysmal nocturnal hemoglobinuria (PNH) never given a complement inhibitor. According to a five-month interim analysis of a Phase 1b proof-of-concept study (NCT05889299), once monthly, under-the-skin…

Treatment with the experimental medication zilucoplan reduced blood cell destruction in previously untreated people with paroxysmal nocturnal hemoglobinuria (PNH) in Phase 2 clinical trials. However, PNH patients who switched to zilucoplan from an approved PNH therapy experienced more blood cell destruction, results showed. That’s according to findings detailed…

A rare disease, paroxysmal nocturnal hemoglobinuria (PNH) affects roughly 1 in of every 237,000 people in Brazil, a study estimates. Its findings shed light on common comorbidities, or co-occurring health conditions like aplastic anemia, affecting PNH patients in that country, as well as the causes of death in those…

The high cost of Soliris (eculizumab) is likely to have catastrophic consequences for people with paroxysmal nocturnal hemoglobinuria (PNH) in Nepal and other places with limited healthcare resources. That’s the argument a team led by scientists in Nepal made in the Orphanet Journal of Rare Diseases, in…

Treatment with crovalimab, an experimental under-the-skin injection therapy, effectively prevented red blood cell death, reduced the need for blood transfusions, and eased fatigue in adults and adolescents with paroxysmal nocturnal hemoglobinuria (PNH). That’s according to a primary analysis of data from the Phase 3 COMMODORE 3 trial (NCT04654468),…

Monthly injections of the experimental therapy crovalimab controlled red blood cell loss and the need for blood transfusions for up to four years in adults with paroxysmal nocturnal hemoglobinuria (PNH), according to data from a long-term extension study. In fact, more than 80% — and up to 92% —…

Treatment with the experimental complement-blocking therapy omoprubart reduced markers of hemolysis, or blood cell destruction, in people with paroxysmal nocturnal hemoglobinuria (PNH). Those findings, from preliminary data of a Phase 1/2 study, were announced by its developer, China-based Canbridge Pharmaceuticals, which now is planning to launch a pivotal…

Chugai Pharmaceutical has applied to regulatory authorities in Japan seeking the approval of crovalimab, an under-the-skin injection therapy that can be administered at home, to treat paroxysmal nocturnal hemoglobinuria (PNH). “We are very pleased that crovalimab, our…

NM3086, an experimental therapy for paroxysmal nocturnal hemoglobinuria (PNH) that’s designed to block the alternative complement pathway’s activation, was generally well tolerated in a first in-human clinical trial. Findings from the Phase 1 study with healthy volunteers suggest NM3086 is working as intended, according to its developer, NovelMed.